Edit Entry

Richard I. Enelow, M.D.

Title(s):
Professor of Medicine
Professor of Microbiology and Immunology
Vice-Chair for Research Affairs, Dept. of Medicine

Department(s):
Medicine
Microbiology and Immunology

Education:
BA Amherst College, 1978
MD Boston University, 1983.
Post-doctoral fellowship, Viral Immunology, University of Virginia, 1992-97

Programs:
Immunology Program
Program in Experimental and Molecular Medicine
SYNERGY
Other

Websites:
http://www.dartmouth.edu/~immuno-cobre/
http://www.dartmouth.edu/~lbcobre/
http://www.dartmouth.edu/~renelowlab/
http://dms.dartmouth.edu/pemm/
http://synergy.dartmouth.edu
http://www.dartmouth.edu/~renelowlab/the-dartmouth-interstitial.html
http://www.dartmouth.edu/~renelowlab/va-lung-immunology-research.html

Contact Information:

1 Medical Center Drive
Lebanon NH 03756

Office: DHMC
Phone: (603) 650-5533
Fax: (603) 650-0580
Email: richard.i.enelow@dartmouth.edu

Assistant: Brittany Bergeron
Asst. Phone: (603) 650-5533
Asst. Email: brittany.j.bergeron@hitchcock.org


Professional Interests:

Immunopathogenesis of respiratory virus infection;
Influenza pathogenesis;
Inflammatory and immune-mediated lung disease

Grant Information:

R01AI069360 (PI: Enelow)
NIH/NIAID
"TNF Processing in Pulmonary Immunopathology"

U19 AI83024 (PI: Enelow)
NIH/NIAID
"Innate Regulation of CD8+ T Cell Effector Activities"

Courses Taught:

Advanced Topics in Immunology
PEMM Immunology Module

Biography:

My area of research broadly concerns the mechanisms that underlie the immune-mediated damage to the lungs which occurs in the context of respiratory virus infection. My clinical interests include immune-mediated lung disease, particularly the idiopathic interstitial pneumonias, and I have spent my entire career exploring the potential relationship between antiviral T cell responses to respiratory infection to chronic inflammatory lung disease. I became interested in host responses to pulmonary infection as a research fellow in Infectious Disease at the University of Virginia, while pursuing clinical training in Pulmonary Disease. I then spent the next 5 years as a post-doctoral fellow in the laboratory of Dr. Thomas J. Braciale, M.D., Ph.D., (Microbiology/Pathology), Director of the newly-established Beirne B. Carter Center for Immunology Research at the University of Virginia, in order to receive rigorous training in viral immunopathogenesis. Aside from outstanding training and mentoring in addressing questions in basic cellular and molecular immunology, I became fascile with the techniques necessary to work with and manipulate negative-strand RNA viruses, such as influenza and RSV, and these respiratory infections have been the focus of most of my work after moving to Yale, and then to Dartmouth. I have extensive experience in mouse and human basic immunology, and my laboratory is currently home to 2 junior faculty members, 3 postdoctoral fellows, 1 graduate student, and 2 research assistants, so I have ample capacity to take on a variety of collaborative projects in addition to our primary areas of exploration. In addition I have 20 years of experience participating in multi-investigator clinical trials, in interstitial lung disease (particularly idiopathic pulmonary fibrosis), my clinical area of interest, and several publications which have come from these endeavors. For information on the Clinical Research Program in Interstitial Lung Disease see http://www.dartmouth.edu/~renelowlab/the-dartmouth-interstitial.html


Selected Publications:

 

Bomberger JM, Ely KH, Bangia N, Ye S, Green KA, Green WR, Enelow RI, Stanton BA
Pseudomonas aeruginosa Cif protein enhances the ubiquitination and proteasomal degradation of the transporter associated with antigen processing (TAP) and reduces major histocompatibility complex (MHC) class I antigen presentation.
J Biol Chem 2014 Jan 3; 289(1):152-62
PMID: 24247241

DeBerge MP, Ely KH, Cheng GS, Enelow RI
ADAM17-mediated processing of TNF-α expressed by antiviral effector CD8+ T cells is required for severe T-cell-mediated lung injury.
PLoS One 2013; 8(11):e79340
PMID: 24223177

Robinson KM, Choi SM, McHugh KJ, Mandalapu S, Enelow RI, Kolls JK, Alcorn JF
Influenza A exacerbates Staphylococcus aureus pneumonia by attenuating IL-1β production in mice.
J Immunol 2013 Nov 15; 191(10):5153-9
PMID: 24089191

Robinson KM, McHugh KJ, Mandalapu S, Clay ME, Lee B, Scheller EV, Enelow RI, Chan YR, Kolls JK, Alcorn JF
Influenza A virus exacerbates Staphylococcus aureus pneumonia in mice by attenuating antimicrobial peptide production.
J Infect Dis 2014 Mar; 209(6):865-75
PMID: 24072844

Farzan SF, Korrick S, Li Z, Enelow R, Gandolfi AJ, Madan J, Nadeau K, Karagas MR
In utero arsenic exposure and infant infection in a United States cohort: a prospective study.
Environ Res 2013 Oct; 126:24-30
PMID: 23769261

Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery AB, Chien JW, O'Riordan TG
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
Ann Intern Med 2013 May 7; 158(9):641-9
PMID: 23648946

Pociask DA, Scheller EV, Mandalapu S, McHugh KJ, Enelow RI, Fattman CL, Kolls JK, Alcorn JF
IL-22 is essential for lung epithelial repair following influenza infection.
Am J Pathol 2013 Apr; 182(4):1286-96
PMID: 23490254

Hufford MM, Richardson G, Zhou H, Manicassamy B, Garcia-Sastre A, Enelow RI, Braciale TJ
Influenza-infected neutrophils within the infected lungs act as antigen presenting cells for anti-viral CD8(+) T cells.
PLoS One 2012; 7(10):e46581
PMID: 23056353

Gifford AH, Matsuoka M, Ghoda LY, Homer RJ, Enelow RI
Chronic inflammation and lung fibrosis: pleotropic syndromes but limited distinct phenotypes.
Mucosal Immunol 2012 Sep; 5(5):480-4
PMID: 22806097

Kozul-Horvath CD, Zandbergen F, Jackson BP, Enelow RI, Hamilton JW
Effects of low-dose drinking water arsenic on mouse fetal and postnatal growth and development.
PLoS One 2012; 7(5):e38249
PMID: 22693606